Comparing the current results to its competitors, Belite Bio Inc reported Revenue decrease in the 4 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 4.56 %, recorded in the same quarter.
Belite Bio Inc's Comment on Competition and Industry Peers
There are currently no FDA-approved treatments for Stargardt disease (STGD1) or orally administered treatments for geographic atrophy (GA). The competitive landscape for STGD1 and GA includes several companies engaged in clinical development. The tinlarebant Phase 3 clinical study is the only completed Phase 3 trial for STGD1, with one other company conducting an ongoing Phase 3 trial. In GA, five companies are advancing treatments, with three in Phase 3 development and two having completed Phase 3 development and received drug approval. Competitors include major and specialty pharmaceutical companies, generic drug companies, academic institutions, government agencies, and research institutions. Many competitors possess greater resources such as capital, technical capabilities, human resources, and regulatory experience. Mergers and acquisitions may further concentrate resources among fewer competitors.
June 12, 2024
Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical company specializing in novel therapies for degenerative retinal diseases, has achieved a significant milestone. On June 12, 2024, the company announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Sakigake (Pioneer Drug) Designation to its lead therapeutic candidate, Tinlarebant, for the treatment of Stargardt disease type 1 (STGD1).The Sakigake Designation is an esteemed status in Japan s pharmaceutical regulatory framework, bestowed upon pioneering drugs that demonstrate substantial potential to address unmet medical needs. This designation is intended to expedite the development and approval process, ensurin...
April 25, 2024
San Diego-based clinical-stage biopharmaceutical drug development company, Belite Bio, Inc (NASDAQ: BLTE), has taken a significant step forward in its fight against degenerative retinal diseases, announcing on April 25, 2024, that it has negotiated a securities purchase agreement with an institutional investor for a registered direct offering. The focus of Belite Bio has always been on progressing pioneering therapeutics for vision-related disorders that currently lack adequate medical solutions. The announcement marks another progression towards their goal.Belite Bio s ground-breaking and relentless pursuit of innovative therapeutic treatment for retinal diseases aligns with the company s original vision o...
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Nascent Biotech Inc's business model is focused on the development and commercialization of innovative therapies in the field of biotechnology. They aim to leverage their expertise and research to bring new drugs to market that can address critical unmet medical needs.
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Sources:
Belite Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Belite Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
